K Biologicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 27 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 15.70%
(FY 2020)
- Profit 127.33%
(FY 2020)
- Ebitda 36.14%
(FY 2020)
- Net Worth 23.35%
(FY 2020)
- Total Assets -15.46%
(FY 2020)
About K Biologicals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Goldy Nagdev and Deepa Nagdev serve as directors at the Company.
- CIN/LLPIN
U51397DL1997PTC089631
- Company No.
089631
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Sep 1997
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at K Biologicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Goldy Nagdev  | Director | 12-Feb-2022 | Current |
| Deepa Nagdev | Director | 16-May-2011 | Current |
Financial Performance of K Biologicals.
K Biologicals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 15.7% increase. The company also saw a substantial improvement in profitability, with a 127.33% increase in profit. The company's net worth Soared by an impressive increase of 23.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of K Biologicals?
In 2018, K Biologicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rising Sun Aromas And Spirituals Private LimitedActive 19 years 8 monthsGoldy Nagdev is a mutual person
Hari Darshan Sevashram Private LimitedActive 31 years 6 monthsGoldy Nagdev and Deepa Nagdev are mutual person
Hari Ashram Products Private LimitedActive 22 years 3 monthsGoldy Nagdev and Deepa Nagdev are mutual person
- Hari Darshan Dhoop And Agarbatti Private LimitedActive 10 months 3 days
Deepa Nagdev is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at K Biologicals?
K Biologicals has a workforce of 22 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of K Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped K Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
